Advertisement

Diabetology International

, Volume 5, Issue 4, pp 207–211 | Cite as

A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy

  • Masakazu HanedaEmail author
  • Kazunori Utsunomiya
  • Daisuke Koya
  • Tetsuya Babazono
  • Tatsumi Moriya
  • Hirofumi Makino
  • Kenjiro Kimura
  • Yoshiki Suzuki
  • Takashi Wada
  • Susumu Ogawa
  • Masaaki Inaba
  • Yoshihiko Kanno
  • Takashi Shigematsu
  • Ikuto Masakane
  • Ken Tsuchiya
  • Keiko Honda
  • Kazuko Ichikawa
  • Kenichiro Shide
Report of the committee

Abstract

The Joint Committee on Diabetic Nephropathy has revised its Classification of Diabetic Nephropathy (Classification of Diabetic Nephropathy 2014) in line with the widespread use of key concepts, such as the estimated glomerular filtration rate (eGFR) and chronic kidney disease. In revising the Classification, the Committee carefully evaluated, as relevant to current revision, the report of a study conducted by the Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan. Major revisions to the Classification are summarized as follows: (1) eGFR is substituted for GFR in the Classification; (2) the subdivisions A and B in stage 3 (overt nephropathy) have been reintegrated; (3) stage 4 (kidney failure) has been redefined as a GFR less than 30 mL/min/1.73 m2, regardless of the extent of albuminuria; and (4) stress has been placed on the differential diagnosis of diabetic nephropathy versus non-diabetic kidney disease as being crucial in all stages of diabetic nephropathy.

Keywords

Diabetic nephropathy Chronic kidney disease (CKD) Albuminuria Proteinuria Glomerular filtration rate (GFR) 

Notes

Acknowledgments

The Joint Committee on Diabetic Nephropathy would like to extend its heartfelt thanks to all investigators in the Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan for their contributions, which provided the basis for the current revision.

Conflict of interest

Masakazu Haneda has received speaker honoraria from pharmaceutical companies Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Daiichi-Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., Sanofi K.K., Merck Sharp & Dohme, Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Kowa Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K., scholarship grants from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Merck Sharp & Dohme, Boehringer Ingelheim GmbH, and Eli Lilly and Company, Daisuke Koya has received speaker honoraria from pharmaceutical companies Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, and Eli Lilly and Company, research grants from Mitsubishi Tanabe Pharma Corporation, Boehringer Ingelheim GmbH, Japan Tabacco Inc., Eli Lilly and Company, and Ono Pharmaceutical Co., Ltd., Tetsuya Babazono has received speaker honoraria from pharmaceutical company Merck Sharp & Dohme, Tatsumi Moriya has received travel expenses from pharmaceutical companies Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and Daiichi-Sankyo Co., Ltd., Hirofumi Makino has received speaker honoraria from pharmaceutical companies AbbVie GK, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Daiichi-Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Novartis Pharma K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co., and Mitsubishi Tanabe Pharma Corporation, research grants from Project for accelerating Practice and Research on Community Medicine in Okayama Prefecture, scholarship grants from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme, Takeda Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corporation, Kenjiro Kimura has received research grants from pharmaceutical companies Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Limited., Boehringer Ingelheim GmbH, Baxter International Inc., and Sekisui Medical Co., Ltd., Takashi Wada has received speaker honoraria from pharmaceutical company Daiichi-Sankyo Co., Ltd., scholarship grants from Chugai pharmaceutical Co., Ltd., Susumu Ogawa has received speaker honoraria from pharmaceutical companies Daiichi-Sankyo Co., Ltd., Eli Lilly and Company, and Novo Nordisk Pharma Ltd., research grants from Daiichi-Sankyo Co., Ltd., Masaaki Inaba has received speaker honoraria from pharmaceutical companies Bayer Yakuhin, Ltd., Takeda Pharmaceutical Co., Ltd., Merck Sharp & Dohme, Kyowa Hakko Kirin Co., Ltd., and Asahi Kasei Pharma Corporation, research grants from Bayer Yakuhin, Ltd., Kyowa Hakko Kirin Co., Ltd., and Eli Lilly and Company, Yoshihiko Kanno has received scholarship grants from pharmaceutical company Chugai Pharmaceutical Co., Ltd., travel expenses from Abbott Japan Co., Ltd., Takashi Shigemats has received research grants from pharmaceutical company Bayer Yakuhin, Ltd., Kazunori Utsunomiya, Yoshiki Suzuki, Ikuto Masakane, Ken Tsuchiya, Keiko Honda, Kazuko Ichikawa, Kenichiro Shide have no conflict of interest.

Human rights statement and informed consent

This article does not contain any studies with human or animal subjects performed by the any of the authors.

References

  1. 1.
    Haneda M, Utsunomiya K, Koya D, et al. On the development of the Classification of Diabetic Nephropathy 2014 (Revised Classification of Diabetic Nephropathy). J Jpn Diab Soc. 2014;57:529–34 (in Japanese).Google Scholar
  2. 2.
    Haneda M, Utsunomiya K, Koya D, et al. On the development of the Classification of Diabetic Nephropathy 2014 (Revised Classification of Diabetic Nephropathy). Jpn J Nephrol. 2014;56:547–52 (in Japanese).Google Scholar
  3. 3.
    Haneda M, Utsunomiya K, Koya D, et al. On the development of the Classification of Diabetic Nephropathy 2014 (Revised Classification of Diabetic Nephropathy). J Jpn Soc Dial Ther. 2014;47:415–9 (in Japanese).CrossRefGoogle Scholar
  4. 4.
    Haneda M, Utsunomiya K, Koya D, et al. On the development of the Classification of Diabetic Nephropathy 2014 (Revised Classification of Diabetic Nephropathy). Clin Nutr. 2014;17:325–30 (in Japanese).Google Scholar
  5. 5.
    Committee for Statistical Surveys, Japanese Society for Dialysis Therapy (JSDT). Current state of dialysis therapy in Japan, 2013 illustrated. http://docs.jsdt.or.jp/overview/index.html
  6. 6.
    Diabetes survey research report. Ministry of Health and Welfare, Japan, 1991. p 320.Google Scholar
  7. 7.
    Yoshikawa R. (Principal investigator) Report of the Joint Committee on Diabetic Nephropathy. 1. On revision of the Ministry of Health, Labour and Welfare Version of the Classification of Diabetic Nephropathy. J Jpn Diab Soc. 2001;44:623 (in Japanese).Google Scholar
  8. 8.
    Guide to the management of chronic kidney disease. CKD. Jpn J Nephrol. 2007;49:767 (in Japanese).Google Scholar
  9. 9.
    Guide to the management of chronic kidney disease (CKD) 2012. Jpn J Nephrol. 2012;54:1047. (in Japanese).Google Scholar
  10. 10.
    Systematic research report from the Research Group of Diabetic Nephropathy, 2009–2012. Ministry of Health, Labour and Welfare, Japan, 2012. P. 1-28. http://mhlw-grants.niph.go.jp/.
  11. 11.
    Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki SI, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Toyama T, Hara A, Makino H, The Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014;18:613–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Guidelines for lifestyle modification/diet therapy in patients with kidney disease. Jpn J Nephrol. 1997;39:1–37 (in Japanese)Google Scholar
  13. 13.
    Summary of revisions for the 2013 clinical practice recommendations. Diabetes Care 2013;36 Suppl 1:S3. doi: 10.2337/dc13-S003
  14. 14.
    Summary of revisions to the 2014 Clinical Practice Recommendations. Diabetes Care 2014;37 Suppl 1:S4. doi: 10.2337/dc14-S004

Copyright information

© The Japan Diabetes Society, Japanese Society of Nephrology, Japanese Society for Dialysis Therapy, and Japan Society of Metabolism and Clinical Nutrition 2014

Authors and Affiliations

  • Masakazu Haneda
    • 1
    Email author
  • Kazunori Utsunomiya
    • 2
  • Daisuke Koya
    • 3
  • Tetsuya Babazono
    • 4
  • Tatsumi Moriya
    • 5
  • Hirofumi Makino
    • 6
  • Kenjiro Kimura
    • 7
  • Yoshiki Suzuki
    • 8
  • Takashi Wada
    • 9
  • Susumu Ogawa
    • 10
    • 19
  • Masaaki Inaba
    • 11
  • Yoshihiko Kanno
    • 12
  • Takashi Shigematsu
    • 13
  • Ikuto Masakane
    • 14
  • Ken Tsuchiya
    • 15
  • Keiko Honda
    • 16
  • Kazuko Ichikawa
    • 17
  • Kenichiro Shide
    • 18
  1. 1.Division of Metabolism and Biosystemic Science, Department of MedicineAsahikawa Medical UniversityAsahikawaJapan
  2. 2.Division of Diabetes, Endocrinology and Metabolism, Department of Internal MedicineJikei University School of MedicineTokyoJapan
  3. 3.Department of Diabetology and EndocrinologyKanazawa Medical UniversityIshikawaJapan
  4. 4.Department of Medicine, Diabetes CenterTokyo Women’s Medical UniversityTokyoJapan
  5. 5.Health Care CenterKitasato UniversitySagamiharaJapan
  6. 6.Okayama University HospitalOkayamaJapan
  7. 7.Division of Nephrology and Hypertension, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan
  8. 8.Health Administration CenterNiigata UniversityNiigataJapan
  9. 9.Division of Nephrology, Department of Laboratory MedicineKanazawa UniversityKanazawaJapan
  10. 10.Center for the Advancement of Higher EducationTohoku UniversitySendaiJapan
  11. 11.Department of Metabolism, Endocrinology, Molecular Medicine, Faculty of MedicineOsaka City University Graduate School of MedicineOsakaJapan
  12. 12.Department of NephrologyTokyo Medical UniversityTokyoJapan
  13. 13.Division of Nephrology, Department of Internal MedicineWakayama Medical UniversityWakayamaJapan
  14. 14.Department of NephrologyYabuki HospitalYamagataJapan
  15. 15.Department of Internal Medicine IVTokyo Women’s Medical UniversityTokyoJapan
  16. 16.Division of Medicine/Nutrition, Department of Applied NutritionKagawa Nutrition UniversitySakadoJapan
  17. 17.Department of NutritionKawasaki Medical School HospitalHiroshimaJapan
  18. 18.Department of Metabolism and Clinical NutritionKyoto University HospitalKyotoJapan
  19. 19.Division of Nephrology, Endocrinology and Vascular MedicineTohoku University HospitalSendaiJapan

Personalised recommendations